title banner

OR in the News

OR in the News (selected articles)

Ruetzler K, Li K, Chhabada S, Maheshwari K, Chahar P, Khanna S, Schmidt MT, Yang D, Turan A, Sessler DI: Sugammadex versus neostigmine for reversal of residual neuromuscular blocks after surgery: A retrospective cohort analysis of postoperative side effects. Anesth Analg 2022; 134: 1043-1053

December 19, 2022

Sugammadex and neostigmine given to reverse residual neuromuscular block- ade can cause side effects including bradycardia, anaphylaxis, bronchospasm, and even cardiac arrest. We tested the hypothesis that sugammadex is noninferior to neostigmine on a compos- ite of clinically meaningful side effects, or vice versa
We analyzed medical records of patients who had general, cardiothoracic, or pedi- atric surgery and were given neostigmine or sugammadex from June 2016 to December 2019. Our primary outcome was a collapsed composite of bradycardia, anaphylaxis, bronchospasm, and cardiac arrest occurring between administration of the reversal agent and departure from the operation room. We a priori restricted our analysis to side effects requiring pharmacologic
treatment that were therefore presumably clinically meaningful. Sugammadex would be consid- ered noninferior to neostigmine (or vice versa) if the odds ratio for composite of side effects did not exceed 1.2
Among 89,753 surgeries in 70,690 patients, 16,480 (18%) were given sugammadex and 73,273 (82%) were given neostigmine. The incidence of composite outcome was 3.4% in patients given sugammadex and 3.0% in patients given neostigmine. The most common indi- vidual side effect was bradycardia (2.4% in the sugammadex group versus 2.2% neostigmine). Noninferiority was not found, with an estimated odds ratio of 1.21 (sugammadex versus neo- stigmine; 95% confidence interval [CI], 1.09–1.34; noninferiority P = .57), and neostigmine was superior to sugammadex with an estimated odds ratio of 0.83 (0.74–0.92), 1-side superiority P < .001. CONCLUSIONS:
The composite incidence was less with neostigmine than with sugammadex, but only by 0.4% (a negligible clinical effect). Since 250 patients would need to be given neo- stigmine rather than sugammadex to avoid 1 episode of a minor complication such as bra- dycardia or bronchospasm, we conclude that sugammadex and neostigmine are comparably safe. (Anesth Analg 2022;134:1043–53)